The Pro 12Ala PPARγ gene polymorphism: Possible modifier of the activity and severity of thyroid-associated orbitopathy (TAO)

Clinical Endocrinology

Volumn 70, Issue 3, 2009, Pages 464-468

  Alevizaki, Maria ^a,b   Mantzou, Emily ^a,b   Cimponeriu, Adriana ^a,b   Saltiki, Katerina ^a,b   Philippou, George ^a,b   Wiersinga, Wilmar ^c  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b Evgenidion Hospital   (Greece)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE SEVERITY; DNA POLYMORPHISM; ENDOCRINE OPHTHALMOPATHY; FEMALE; GENE FREQUENCY; GRAVES DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTPATIENT DEPARTMENT; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AGED; COHORT STUDIES; FEMALE; GENE FREQUENCY; GRAVES DISEASE; GRAVES OPHTHALMOPATHY; GREECE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NETHERLANDS; ORBITAL DISEASES; POLYMORPHISM, SINGLE NUCLEOTIDE; PPAR GAMMA; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 60349088829     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/j.1365-2265.2008.03343.x     Document Type: Article

References (34)

1. Bahn, R.S. (2003) Clinical review 157: pathophysiology of Graves' ophthalmopathy: the cycle of disease. Journal of Clinical Endocrinology and Metabolism, 88, 1939 1946.
2. Bednarczuk, T., Gopinath, B., Ploski, R. et al. (2007) Susceptibility genes in Graves' ophthalmopathy: searching for a needle in a haystack? Clinical Endocrinology, 67, 3 19.
3. Bartalena, L., Pinchera, A. Marcocci, C. (2000) Management of Graves' ophthalmopathy: reality and perspectives. Endocrine Reviews, 21, 168 199.
4. Orgiazzi, J. (2007) Pathogenesis, In : W.M. Wiersinga, G.J. Kahaly eds. Graves' Orbitopathy: a Multidisciplinary Approach, S.KARGER AG, Basel, Switzerland. pp. 41 56.
5. Kumar, S., Coenen, M.J., Scherer, P.E. et al. (2004) Evidence for enhanced adipogenesis in the orbits of patients with Graves' ophthalmopathy. Journal of Clinical Endocrinology and Metabolism, 89, 930 935.
6. Lantz, M., Vondrichova, T., Parikh, H. et al. (2005) Overexpression of immediate early genes in active Graves' ophthalmopathy. Journal of Clinical Endocrinology and Metabolism, 90, 4784 4791.
7. Kumar, S., Leontovich, A., Coenen, M.J. et al. (2005) Gene expression profiling of orbital adipose tissue from patients with Graves' ophthalmopathy: a potential role for secreted frizzled-related protein-1 in orbital adipogenesis. Journal of Clinical Endocrinology and Metabolism, 90, 4730 4735.
8. Jyonouchi, S.C., Valyasevi, R.W., Harteneck, D.A. et al. (2001) Interleukin-6 stimulates thyrotropin receptor expression in human orbital preadipocyte fibroblasts from patients with Graves' ophthalmopathy. Thyroid, 11, 929 934.
9. Valyasevi, R.W., Harteneck, D.A., Dutton, C.M. et al. (2002) Stimulation of adipogenesis, peroxisome proliferator-activated receptor-γ (PPARγ), and thyrotropin receptor by PPARγ agonist in human orbital preadipocyte fibroblasts. Journal of Clinical Endocrinology and Metabolism, 87, 2352 2358.
10. Mimura, L.Y., Villares, S.M., Monteiro, M.L. et al. (2003) Peroxisome proliferator-activated receptor-γ gene expression in orbital adipose/connective tissues is increased during the active stage of Graves' ophthalmopathy. Thyroid, 13, 845 850.
11. Pasquali, D., Pierantoni, G.M., Fusco, A. et al. (2004) Fenofibrate increases the expression of high mobility group AT-hook 2 (HMGA2) gene and induces adipocyte differentiation of orbital fibroblasts from Graves' ophthalmopathy. Journal of Molecular Endocrinology, 33, 133 143.
12. Zhang, L. Chawla, A. (2004) Role of PPARγ in macrophage biology and atherosclerosis. Trends in Endocrinology and Metabolism, 15, 500 505.
13. Dorkhan, M., Lantz, M., Frid, A. et al. (2006) Treatment with a thiazolidinedione increases eye protrusion in a subgroup of patients with type 2 diabetes. Clinical Endocrinology, 65, 35 39.
14. Starkey, K., Heufelder, A., Baker, G. et al. (2003) Peroxisome proliferator-activated receptor-γ in thyroid eye disease: contraindication for thiazolidinedione use? Journal of Clinical Endocrinology and Metabolism, 88, 55 59.
15. Lee, S., Tsirbas, A., Goldberg, R.A. et al. (2007) Thiazolidinedione induced thyroid associated orbitopathy. BMC Ophthalmology, 7, 8.
16. Deeb, S.S., Fajas, L., Nemoto, M. et al. (1998) A Pro12Ala substitution in PPARγ2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nature Genetics, 20, 284 287.
17. Masugi, J., Tamori, Y., Mori, H. et al. (2000) Inhibitory effect of a proline-to-alanine substitution at codon 12 of peroxisome proliferator-activated receptor-γ 2 on thiazolidinedione-induced adipogenesis. Biochemical and Biophysical Research Communications, 268, 178 182.
18. Al-Shali, K.Z., House, A.A., Hanley, A.J. et al. (2004) Genetic variation in PPARG encoding peroxisome proliferator-activated receptor γ associated with carotid atherosclerosis. Stroke, 35, 2036 2040.
19. Temelkova-Kurktschiev, T., Hanefeld, M., Chinetti, G. et al. (2004) Ala12Ala genotype of the peroxisome proliferator-activated receptor gamma2 protects against atherosclerosis. Journal of Clinical Endocrinology and Metabolism, 89, 4238 4242.
20. Bartalena, L., Baldeschi, L., Dickinson, A. et al. (2008) Consensus statement of the European Group on Graves' orbitopathy (EUGOGO) on management of GO. European Journal of Endocrinology, 158, 273 285.
21. Perros, P., Crombie, A.L., Matthews, J.N. et al. (1993) Age and gender influence the severity of thyroid-associated ophthalmopathy: a study of 101 patients attending a combined thyroid-eye clinic. Clinical Endocrinology, 38, 367 372.
22. Gerding, M.N., van der Meer, J.W., Broenink, M. et al. (2000) Association of thyrotrophin receptor antibodies with the clinical features of Graves' ophthalmopathy. Clinical Endocrinology, 52, 267 271.
23. Eckstein, A.K., Plicht, M., Lax, H. et al. (2006) Thyrotropin receptor autoantibodies are independent risk factors for Graves' ophthalmopathy and help to predict severity and outcome of the disease. Journal of Clinical Endocrinology and Metabolism, 91, 3464 3470.
24. Sharma, A.M. Staels, B. (2007) Review: peroxisome proliferator-activated receptor γ and adipose tissue - understanding obesity-related changes in regulation of lipid and glucose metabolism. Journal of Clinical Endocrinology and Metabolism, 92, 386 395.
25. Vondrichova, T., de Capretz, A., Parikh, H. et al. (2007) COX-2 and SCD, markers of inflammation and adipogenesis, are related to disease activity in Graves' ophthalmopathy. Thyroid, 17, 511 517.
26. Antonelli, A., Rotondi, M., Ferrari, S.M. et al. (2006) Interferon-γ-inducible α-chemokine CXCL10 involvement in Graves' ophthalmopathy: modulation by peroxisome proliferator-activated receptor-γ agonists. Journal of Clinical Endocrinology and Metabolism, 91, 614 620.
27. Hiromatsu, Y., Yang, D., Bednarczuk, T. et al. (2000) Cytokine profiles in eye muscle tissue and orbital fat tissue from patients with thyroid-associated ophthalmopathy. Journal of Clinical Endocrinology and Metabolism, 85, 1194 1199.
28. Kumar, S. Bahn, R.S. (2003) Relative overexpression of macrophage-derived cytokines in orbital adipose tissue from patients with graves' ophthalmopathy. Journal of Clinical Endocrinology and Metabolism, 88, 4246 4250.
29. Smith, T.J. (2002) Orbital fibroblasts exhibit a novel pattern of responses to proinflammatory cytokines: potential basis for the pathogenesis of thyroid-associated ophthalmopathy. Thyroid, 12, 197 203.
30. Wakelkamp, I.M., Bakker, O., Baldeschi, L. et al. (2003) TSH-R expression and cytokine profile in orbital tissue of active vs. inactive Graves' ophthalmopathy patients. Clinical Endocrinology, 58, 280 287.
31. Feldon, S.E., O'Loughlin, C.W., Ray, D.M. et al. (2006) Activated human T lymphocytes express cyclooxygenase-2 and produce proadipogenic prostaglandins that drive human orbital fibroblast differentiation to adipocytes. The American Journal of Pathology, 169, 1183 1193.
32. Hasegawa, H., Takano, H., Zou, Y. et al. (2005) Pioglitazone, a peroxisome proliferator-activated receptor γ activator, ameliorates experimental autoimmune myocarditis by modulating Th1/Th2 balance. Journal of Molecular Cellular Cardiology, 38, 257 265.
33. Straus, D.S. Glass, C.K. (2007) Anti-inflammatory actions of PPAR ligands: new insights on cellular and molecular mechanisms. Trends in Immunology, 28, 551 558.
34. Wolford, J.K., Yeatts, K.A., Dhanjal, S.K. et al. (2005) Sequence variation in PPARG may underlie differential response to troglitazone. Diabetes, 54, 3319 3325.